<DOC>
	<DOCNO>NCT02826798</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness four different dos cytomegalovirus vaccine healthy adult .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Immunogenicity Candidate Human Cytomegalovirus Vaccine Healthy Adults</brief_title>
	<detailed_description>This study design assess safety immunogenicity four dose formulation cytomegalovirus ( CMV ) vaccine ( 0.5 μg gB content aluminum phosphate ( alum ) , 1.0 μg glycoprotein B ( gB ) content alum , 2.0 μg gB content alum , 1.0 μg gB content ( without alum ) compare placebo approximately 125 healthy CMV-seronegative volunteer participant 18 40 year age .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Generally healthy adult female male 18 40 year age , inclusive ; 2 . Serologically confirm CMV seronegative screening ; 3 . Female volunteer must agree use adequate contraception method deem appropriate investigator 4 . Sign inform consent document indicate understand purpose procedure require study willingness participate study 1 . History current clinically significant medical illness illness opinion investigator interfere interpretation study result 2 . Clinically significant abnormal physical examination , vital sign , clinically significant abnormal value hematology , clinical chemistry urinalysis screening determine investigator 3 . Previous receipt cytomegalovirus vaccine 4 . History allergic reaction anaphylactic reaction vaccine component 5 . Pregnant breastfeeding plan conceive two week study start six month last dose study vaccine 6 . Known suspected impairment immunological function , include limited autoimmune disease , splenectomy , HIV/AIDS 7 . Chronic administration ( defined 14 day total ) immunesuppressive immunemodifying drug six month prior product dose ( corticosteroid , define prednisone ≥20 mg/day equivalent ) . Inhaled topical steroid allow 8 . Participation another clinical study within 30 day plan participate another treatment base clinical study conduct present study 9 . Any skin abnormality tattoo would limit postvaccination injection site assessment 10 . Any history cancer require chemotherapy radiation within 5 year randomization current disease 11 . Are family member study center staff</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>VBI-1501A</keyword>
	<keyword>VBI-1501</keyword>
	<keyword>prophylactic vaccine</keyword>
	<keyword>virus disease</keyword>
	<keyword>cytomegalovirus</keyword>
	<keyword>CMV</keyword>
	<keyword>cytomegalovirus infection</keyword>
	<keyword>cytomegalovirus vaccine</keyword>
	<keyword>Herpesviridae Infections</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Human Herpesvirus 5</keyword>
	<keyword>HHV5</keyword>
	<keyword>Vaccines , virus-like particle</keyword>
	<keyword>VLP</keyword>
	<keyword>envelop virus-like particle</keyword>
	<keyword>eVLP</keyword>
</DOC>